RE: Indian variant16 May 2021 12:37
If they were to change the structure of the affimer they would have to go through safety and effectiveness testing and clinical trials once again which wouldnt be favourable right now. By far the best option is to ensure that the mutation hasn't altered the binding site of the affimer on the S protein although it may take some time to get access to samples.